Galectin Advances Belapectin Program, Secures New Insider Financing

Galectin Therapeutics ( (GALT) ) has issued an update.

On December 19, 2025, Galectin Therapeutics reported that the U.S. Food and Drug Administration provided a written response to the company’s Type C meeting request on the development program for belapectin, leading the company to believe there is regulatory alignment on the proposed patient population for a future registration trial in MASH cirrhosis. The company plans a follow-up Type C meeting to finalize remaining trial design details and to present new biomarker data, viewing this interaction as a key step toward a pivotal Phase 3 study and an opportunity to integrate input from external key opinion leaders, which it sees as important for advancing belapectin’s clinical strategy. Separately on December 19, 2025, Galectin Therapeutics entered into a new unsecured, convertible line of credit of up to $10 million with its chairman, Richard E. Uihlein, and extended the maturity of all his existing convertible credit lines and notes to June 30, 2027, a move that, together with existing cash, is expected to fund operations through at least March 2027 and underscores continued insider financial support as the company progresses its late-stage liver disease program.

The most recent analyst rating on (GALT) stock is a Buy with a $11.00 price target. To see the full list of analyst forecasts on Galectin Therapeutics stock, see the GALT Stock Forecast page.

Spark’s Take on GALT Stock

According to Spark, TipRanks’ AI Analyst, GALT is a Underperform.

Galectin Therapeutics is a high-risk investment due to its challenging financial position, characterized by no revenues and high financial losses. However, the company’s progress in clinical trials and potential partnerships offer a positive long-term outlook. Technical indicators suggest mixed short-term momentum, while traditional valuation metrics are less applicable due to ongoing losses and the absence of dividends.

To see Spark’s full report on GALT stock, click here.

More about Galectin Therapeutics

Galectin Therapeutics Inc., based in Norcross, Georgia, is a biotechnology company focused on developing galectin-3-targeted therapeutics for chronic liver disease and cancer. Its lead drug candidate, belapectin, a carbohydrate-based galectin-3 inhibitor with U.S. FDA Fast Track designation, is being developed primarily for metabolic dysfunction-associated steatohepatitis (MASH) with cirrhosis and portal hypertension, while additional programs explore its use in combination immunotherapy for advanced head and neck cancers and other malignancies, subject to funding and partnerships.

Average Trading Volume: 393,516

Technical Sentiment Signal: Buy

Current Market Cap: $417.2M

For detailed information about GALT stock, go to TipRanks’ Stock Analysis page.